GeNeuro
Geneva
About GeNeuro
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $54.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: epa:GNRO
- Website: geneuro.com
- Phone: +41227945085
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/geneuro-177214 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.